Janux Therapeutics

Company snapshot

Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. Janux is using its platform masking technology to engineer novel drug candidates that are designed to overcome the traditional T cell engager toxicity and efficacy limitations. Janux is proud

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Janux Therapeutics. Not investment advice.

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Janux Therapeutics.

1. May 23, 2026 Clinical update

   JANX007 — Phase 1

2. May 23, 2026 Clinical update

   JANX008 — Phase 1

3. May 23, 2026 Clinical update

   JANX011 — Phase 1

4. May 23, 2026 Clinical update

   JANX014 — Phase 1

5. Dec 10, 2024 Patent grant

   Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens

View all clinical trial activity →

• What is Janux Therapeutics?

  Janux Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker JANX. Primary therapeutic focus areas include Prostate Cancer, Autoimmune, Non-Small Cell Lung Cancer. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 2

• Is Janux Therapeutics publicly traded?

  Yes. Janux Therapeutics is listed with ticker JANX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Janux Therapeutics develop or market?

  No drug profiles are currently linked to Janux Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Janux Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Janux Therapeutics focus on?

  Janux Therapeutics focuses on Prostate Cancer, Autoimmune, Non-Small Cell Lung Cancer based on our analysis of their pipeline programs and drug development activities.